Biomolecules, Vol. 13, Pages 960: Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus

Biomolecules, Vol. 13, Pages 960: Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus

Biomolecules doi: 10.3390/biom13060960

Authors: Shingo Nakayamada Yoshiya Tanaka

The treatment of rheumatoid arthritis was revolutionized with the use of molecular-targeted drugs that target immunoregulatory molecules. The success of treatment with these drugs prompted the development of molecular-targeted drugs for systemic lupus erythematosus. However, systemic lupus erythematosus is a disease with high heterogeneous immune abnormalities, and diverse cells or molecules can be treatment targets. Thus, the identification of subpopulations based on immune abnormalities is essential for the development of effective treatment. One analytical method used to identify subpopulations is the immunophenotyping of peripheral blood samples of patients. This analysis evaluates the validity of target molecules for peripheral blood immune cell subsets, which are expected to be developed as biomarkers for precision medicine in which appropriate treatment targets are set for each subpopulation.